Transpire Bio announces second agreement with Recipharm for the development of two additional inhaled medicines
Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a second definitive agreement with Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).
TRB-3 and TRB-4, marking the rapid progression of the Transpire Bio pipeline, are inhaled products being developed for advanced markets. With a focus on streamlining the development process, these two new products will expand Transpire Bio’s reach as it looks to bring new, complex inhaled medicines to market.
“We are continuing our relentless pursuit of improving access to important, life-saving inhaled therapies, while methodically building capabilities for new inhaled therapies which will help address areas of significant unmet medical need”, said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “With TRB-3 and TRB-4 we are demonstrating our ability to rapidly progress our pipeline in an effort to meet patient needs as quickly as possible. We are very excited to again be working with Recipharm to advance these important medicines.”
Jean-Francois Hilaire, Executive Committee Member, Head of Business Unit Advanced Delivery Systems added: “TRB-3 and TRB-4 are exciting developments for the treatment of two increasingly common chronic respiratory conditions. Recipharm is delighted to collaborate with Transpire Bio again and we will continue to share our extensive experience and expertise in developing and commercializing inhalation products to help bring these new inhaled medicines to market.”
According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.
It was announced earlier this year that Transpire Bio had entered into an agreement with Recipharm for the development and commercialization of TRB-1 and TRB-2.
About Transpire Bio
Transpire Bio Inc. is a US-based, development-stage biopharmaceutical company headquartered in Miami, Florida. The mission of Transpire Bio is to harness the power of inhaled drug delivery to improve patient access to important therapies and develop treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio develops multiple inhaled approaches, including metered-dose inhalers, soft-mist inhalers, and dry powder inhalers.
For more information, please visit www.transpirebio.com
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com
Contact information:
Marcus Smith, Head of Communications at Recipharm, marcus.smith@recipharm.com
Sunny Zhao, Manager at Transpire Bio, Sunny.Zhao@Transpirebio.com
Recipharm AB
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
Tags: